Nanomedicine Market 2021
Global Nanomedicine Market was valued at US$ 200.10 billion in 2020 and is expected to reach US$ 398.01 billion by 2029 growing at a CAGR of 10.45% over the forecast period. Use of nanotechnology in the field of medical science brings latest helps in development of new strategies in an attempt to prevent, diagnose and treat any kind of disease. This also holds correct in regards with novel COVID-19. The management of the COVID-19 can be done by introduction of nano-based products like personal protective equipment (PPE), disinfectants and diagnostic systems.
Rise in the number of people suffering from cancer and cardiovascular diseases is driving the Nanomedicine Market. Effective treatment and diagnostics of these diseases can be done with the help of nanoscale technologies and nanomedicine, which is much more personalized. Latest advancements in terms of drug delivery is also taking this market ahead.
Access Full Report Details and Order this Premium Report @ https://www.absolutemarketsinsights.com/reports/Nanomedicine--Market-2021---2029-863
Major Key Players:
Some of the major players operating in the Nanomedicine Market include Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals Inc, Johnson & Johnson, Mallinckrodt plc., Merck & Company Inc., Nanosphere Inc. Pfizer Inc. and Teva Pharmaceutical Industries Ltd amongst others.
Key Findings of the Report:
The nanomedicines market in the United States accounts for highest revenue share primarily because of the presence of more advanced healthcare facilities and increased awareness about nanomedicines in the people
The need for effective therapeutics on the basis of nanomedicine in the disease management is likely to drive this market further.
The Nanomedicine Market is expected to witness growth from the neurological diseases segment
The treatment and prevention of COVID-19 is highly dependent in vaccines, and this is expected to benefit the nanomedicines market
Absolute Markets Insights